BPH GlobalASX:BP8 PEG Ratio is 0.00 as of Jul. 01, 2026. The stock has 6 warning signs investors should review. Among 349 Drug Manufacturers companies, BPH Global ranks worse than 286532.66% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, BPH Global's PE Ratio without NRI is 0.00. BPH Global's 5-Year EBITDA growth rate is 32.90%. Therefore, BPH Global's PEG Ratio for today is 0.00.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for BPH Global's PEG Ratio or its related term are showing as below:
ASX:BP8's PEG Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.69 * Ranked among companies with meaningful PEG Ratio only.
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
BPH Global (ASX:BP8) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
BPH Global PEG Ratio Related Terms
BPH Global PEG Ratio Historical Data
* Premium members only.
The historical data trend for BPH Global's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, BPH Global's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BPH Global PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, BPH Global's PEG Ratio distribution charts can be found below:
* The bar in red indicates where BPH Global's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
BPH Global (ASX:BP8) has a PEG Ratio of 0.00 as of Jul. 01, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BPH Global and its competitors. According to the industry distribution chart, BPH Global ranks #999999 out of 349 companies in the Drug Manufacturers industry.
Is BPH Global's PEG Ratio too high?
BPH Global's current PEG Ratio is 0.00. Based on the distribution chart, BPH Global ranks #999999 out of 349 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does BPH Global's PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, BPH Global ranks #999999 out of 349 companies for PEG Ratio. This places BPH Global in the lower half of its industry. The industry median PEG Ratio is 1.69. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.69, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on BPH Global and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BPH Global's current PEG Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BPH Global stock overvalued right now?
BPH Global (ASX:BP8) has a current PEG Ratio of 0.00. The current PEG Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For BPH Global (ASX:BP8), the current PEG Ratio is 0.00 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BPH Global Ltd is a plant-focused biotechnology company with a focus on producing foods, health, and cosmetic products that deliver Traditional Chinese Medicine (TCM)-based health outcomes. It focuses on the research, development, production, and commercialization of TCM products, including bird's nest, seaweeds, and sea plants, which serve as sustainable plant-based protein sources and ingredients for food, nutrition, healthcare, cosmetics, and personal care industries. The company's geographical segment includes Australia, Indonesia, and China. The company's products comprise raw and processed bird's nest, sea grapes (Caulerpa lentillifera), and other seaweeds and sea plants.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:BP8 has been successfully added to your 